Gynecologic Oncology at UWMC

Medical Discoveries

New drugs and therapies available via clinical trials

Gynecologic Cancer Clinical Trials

Our patients have access to new or innovative treatments available only through clinical trials, which may not be offered at other clinics or treatment centers.  For gynecologic cancer patients, this means more treatment options than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at UW Medicine and its partner organizations, Fred Hutch and Seattle Cancer Care Alliance.

Below is a list of gynecologic cancer clinical trials that are currently open and accepting patients. For general information please call our clinic to schedule your appointment at 206-598-8300.


GY004 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 

View more information about study GY004 at clinicaltrials.gov.


GY005 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

View more information about study GY005 at clinicaltrials.gov.


GOG 0225 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 

View more information about study GOG 0225 at clinicaltrials.gov.


GOG 281 MEK Inhibitor Trametanib v. SOC (5 choices) for recur low grade serous ovary

View more information about study GOG 0225 at clinicaltrials.gov.


UW 7750 Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

View more information about study UW 7750 at clinicaltrials.gov.


GOG 0286B Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

View more information about study GOG 0286B at clinicaltrials.gov.


GOG 0263 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

View more information about study GOG 0263 at clinicaltrials.gov.


RTOG/GOG 0724 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy  

View more information about study RTOG/GOG 0724 at clinicaltrials.gov.


NCI-MATCH EAY131 TNCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

View more information about study NCI-MATCH EAY131 TNCI-MATCH at clinicaltrials.gov.


Phase 1 Study of FPA008 (anti-CSF1R mAb) in Combination With Nivolumab in Patients With Selected Advanced Cancers

View more information about Phase 1 Study of FPA008 (anti-CSF1R mAb) at clinicaltrials.gov.


CheckMate358 Phase 1/2 Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors

View more information about study CheckMate358 at clinicaltrials.gov.


9740 Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

View more information about study 9740 at clinicaltrials.gov.


JAVELIN Ovarian 200 A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (msb0010718c) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer

View more information about study JAVELIN Ovarian 200 at clinicaltrials.gov.


A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery

View more information at clinicaltrials.gov